Skip to main content
. 2024 Jul 3;24:138. doi: 10.1186/s12894-024-01521-9

Table 3.

Results of molecular targets prediction

SN Ligands % Probability of predicted targets
A B C D E F G H I J K L M N O P Q R S
1 Dexverapamil 100 100 100 100
2 Emetine 58 40
3 Parthenolide 63 63
4 Dobutamine 100 100 100 100 100 100 100
5 Terfenadine 100 100 100 100 100 100 100 52
6 Pimozide 98 98 98 98
7 Mefloquine 100 90 98
8 Ellipticine 100
9 Trifluoperazine 35 100 33 100 40 26 100

Serotonin receptor 2a/2b/2c (HTR2A/HTR2B/HTR2C, P28223/ P41595/P28335). B: HERG (KCNH2, Q12809). C: Adrenergic receptor Alpha-1a/Alpha-2a (ADRA1A /ADRA2A, P35348/P08913). D: Dopamine D3 receptor (DRD3, P35462). E: Small conductance calcium-activated potassium channel protein 1/2/3 (KCNN1/KCNN2/KCNN3, Q92952/Q9H2S1/Q9UGI6). F: Cyclooxygenase-2 (PTGS2, P35354). G: Nitric oxide synthase, inducible (by homology) (NOS2, P35228). H: Adrenergic receptor Alpha-1d/beta-1 (ADRA1D/ADRB1, P25100/P08588). I: Carbonic anhydrase I, II, III, IV, VA, VB, VI, VII, IX, XII, XIII (CA1/CA2/CA3/ CA4/ CA5A/ CA5B/ CA6/ CA7/ CA9, CA12, CA13, P00915/ P00918/ P07451/ P22748/ P35218/ Q9Y2D0/ P23280/ P43166/ Q16790/ O43570/ Q8N1Q1). J: Epidermal growth factor receptor erbB1 (EGFR, P00533). K: Tyrosine-protein kinase FYN/LCK (FYN/LCK, P06241/ P06239). L: Norepinephrine transporter (SLC6A2, P23975). M: C-C chemokine receptor type 5 (CCR5, P51681). N: Muscarinic acetylcholine receptor M1/M2/M4 (CHRM1/CHRM2/CHRM4, P11229/P08172/P08173. O: Ubiquitin carboxylterminal hydrolase 1 (USP1, O94782). P: Glycine receptor subunit alpha-1 (GLRA1, P23415). Q: Adenosine receptor A1,A2a, A2b, A3 (ADORA1, ADORA2a, ADORA2b ADORA3, P30542/P29274/ P29275/P0DMS8). R: DNA topoisomerase II alpha (TOP2A, P11388). S: Anti-estrogen binding site (AEBS) (EBP, Q15125)